Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of Lipid Research|March 13, 2021
Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos)Matteo Pedrelli, Paolo Parini, Jonas Kindberg, et al.
Plos One|February 27, 2016
Lipoprotein X Causes Renal Disease in LCAT DeficiencyAlice Ossoli, Edward B Neufeld, Seth G Thacker, et al.
Biomedicines|December 23, 2020
HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD)Alessia Di Costanzo, Annalisa Ronca, Laura D'Erasmo, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 5, 2025
Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE<sup>-/-</sup> miceChiara Macchi, Isabella Fichtner, Tasnim Mohamed, et al.
Atherosclerosis|October 9, 2023
Generation and validation of a classification model to diagnose familial hypercholesterolaemia in adultsJoão Albuquerque, Ana Margarida Medeiros, Ana Catarina Alves, et al.
Circulation|November 29, 2023
Flipped C-Terminal Ends of APOA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLsYi He, Chiara Pavanello, Patrick M Hutchins, et al.
Medrxiv : the Preprint Server for Health Sciences|November 14, 2023
Flipped C-Terminal Ends of APOA1 Promote ABCA1-dependent Cholesterol Efflux by Small HDLsYi He, Chiara Pavanello, Patrick M Hutchins, et al.
Advances in Therapy|April 23, 2017
Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in ItalyLaura D'Erasmo, Angelo Baldassare Cefalù, Davide Noto, et al.
Elife|January 27, 2023
Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open-label interventional studyAvner Ehrlich, Konstantinos Ioannidis, Makram Nasar, et al.
Orphanet Journal of Rare Diseases|September 9, 2021
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective surveyLaura D'Erasmo, Antonio Gallo, Angelo Baldassare Cefalù, et al.
Pageof 10